Media coverage about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) has been trending positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cardiome Pharma earned a media sentiment score of 0.33 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.3592814148547 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s analysis:
- Marapharm Ventures Inc. Appoints Corey Klassen as Vice President of Corporate Development, Hires CFO and Adds Additional Independent Director (finance.yahoo.com)
- Cardiome Pharma (CRME) Scheduled to Post Quarterly Earnings on Tuesday (americanbankingnews.com)
- Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13 (finance.yahoo.com)
- Cardiome Pharma Corp (CRME) Position Lifted by Stonepine Capital Management LLC (americanbankingnews.com)
- Tamarack Advisers LP Boosts Position in Cardiome Pharma Corp (CRME) (americanbankingnews.com)
Cardiome Pharma (CRME) traded down $0.03 during midday trading on Friday, reaching $1.65. The company had a trading volume of 28,212 shares, compared to its average volume of 51,008. Cardiome Pharma has a 1 year low of $1.29 and a 1 year high of $4.84. The stock has a market capitalization of $58.18, a P/E ratio of -1.96 and a beta of 0.65. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3253711/favorable-media-coverage-somewhat-unlikely-to-impact-cardiome-pharma-crme-stock-price.html.
About Cardiome Pharma
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.